🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Joel Greenblatt’s DFTX Holdings & Trades

First Buy
Q2 2026
Duration Held
1 Quarters
Largest Add
Q2 2026
+4,412 Shares
Current Position
4,412 Shares
$207,540 Value

Joel Greenblatt's DFTX Position Overview

Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 4,412 shares of Definium Therapeutics, Inc. (DFTX) worth $207,540, representing 0.00% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Joel Greenblatt has initiated a new position in DFTX, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Joel Greenblatt's Definium Therapeutics (DFTX) Holding Value Over Time

Track share changes against reported price movement

Quarterly Definium Therapeutics (DFTX) Trades by Joel Greenblatt

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +4,412 New Buy 4,412 $47.04

Joel Greenblatt's Definium Therapeutics Investment FAQs

Joel Greenblatt first purchased Definium Therapeutics, Inc. (DFTX) in Q2 2026, acquiring 4,412 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Joel Greenblatt has held Definium Therapeutics, Inc. (DFTX) for 1 quarters since Q2 2026.

Joel Greenblatt's largest addition to Definium Therapeutics, Inc. (DFTX) was in Q2 2026, adding 4,412 shares worth $207,540.

According to the latest 13F filing for Q2 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 4,412 shares of Definium Therapeutics, Inc. (DFTX), valued at approximately $207,540.

As of the Q2 2026 filing, Definium Therapeutics, Inc. (DFTX) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.

Joel Greenblatt's peak holding in Definium Therapeutics, Inc. (DFTX) was 4,412 shares, as reported at the end of Q2 2026.